Financials in USD. Standardized financial statements.
A compact view of how REGENXBIO Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $170.44M | $83.33M | $90.24M | $112.72M | $470.35M | $154.57M | $35.23M | $218.50M | $10.39M | $4.59M |
| Revenue Growth? | +104.5% | -7.7% | -19.9% | -76.0% | +204.3% | +338.7% | -83.9% | +2002.4% | +126.5% | 0.0% |
| Cost of Revenue? | $20.30M | $33.57M | $37.21M | $54.55M | $51.83M | $35.71M | $8.24M | $9.64M | $1.71M | $959,000 |
| Gross Profit? | $150.14M | $49.76M | $53.03M | $58.18M | $418.51M | $118.85M | $26.99M | $208.87M | $8.68M | $3.63M |
| Gross Margin? | +88.1% | +59.7% | +58.8% | +51.6% | +89.0% | +76.9% | +76.6% | +95.6% | +83.6% | +79.1% |
| Operating Expenses? | $311.34M | $283.11M | $321.16M | $321.06M | $258.53M | $238.09M | $175.99M | $120.77M | $84.57M | $68.97M |
| Operating Income? | -$161.20M | -$233.35M | -$268.13M | -$262.88M | $159.98M | -$119.23M | -$149.00M | $88.10M | -$75.89M | -$65.34M |
| EBITDA? | -$145.58M | -$198.23M | -$239.46M | -$244.24M | $169.54M | -$96.83M | -$90.34M | $92.08M | -$73.20M | -$64.80M |
| Income Before Tax | -$193.88M | -$227.10M | -$263.65M | -$280.40M | $141.25M | -$106.01M | -$97.49M | $104.12M | -$73.17M | -$63.40M |
| Income Tax Expense | $0 | $0 | -$152,000 | -$84,000 | $13.41M | $5.24M | -$2.75M | $4.18M | $686,000 | -$435,000 |
| Net Income? | -$193.88M | -$227.10M | -$263.49M | -$280.32M | $127.84M | -$111.25M | -$94.73M | $99.94M | -$73.17M | -$62.97M |
| EPS? | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $3.01 | $-2.98 | $-2.58 | $2.73 | $-2.45 | $-2.38 |
| Diluted EPS? | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $2.91 | $-2.98 | $-2.58 | $2.73 | $-2.45 | $-2.38 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality